Effect of blood pressure lowering on markers of kidney disease progression
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hypertension remains a common comorbidity and cause of chronic kidney disease (CKD). As the number of patients with CKD grows, so does the need to identify modifiable risk factors for CKD progression. Data on slowing progression of CKD or preventing end-stage renal disease with aggressive blood pressure control have not yielded definitive conclusions regarding ideal blood pressure targets. Shifting the focus of antihypertensive therapy to alternative markers of end-organ damage, specifically proteinuria, has yielded some promise in preventing the progression of CKD. Nevertheless, proteinuria and decline in estimated GFR may represent an irreversible degree of injury to the kidney that limits the impact of any therapy. The identification and use of novel markers of kidney injury to assess the impact of antihyper tensive therapy may yield clearer direction with regard to optimal management of hypertension in the setting of CKD.
- Abu Jawdeh BG, Rahman M: Blood pressure level and kidney disease progression: do we really need to go to 130/80 mm Hg? Curr Hypertens Rep 2009, 11:363–367. CrossRef
- Klag MJ, Whelton PK, Randall BL, et al.: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334:13–18. CrossRef
- Hsu C, McCulloch CE, Darbinian J, et al.: Elevated blood pressure and risk for end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165:923–928. CrossRef
- Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994, 330:877–884. CrossRef
- Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria and the progression of renal disease—the Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.
- Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421–2431. CrossRef
- Appel LJ, Wright JT Jr, Greene T, et al.: Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008, 168:832–839. CrossRef
- Toto RD, Mitchell HC, Smith RD, et al.: “Strict” blood pressure control and risk of renal disease in hypertensive nephrosclerosis. Kidney Int 1995, 48:851–859. CrossRef
- Lea J, Greene T, Hebert L, et al.: The relationship of magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2005, 165:947–953. CrossRef
- UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713.
- Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860. CrossRef
- Atkins RC, Briganti EM, Lewis JB, et al.: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2004, 45:281–287. CrossRef
- Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. CrossRef
- Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL Study. Arch Intern Med 2003, 163:1555–1565. CrossRef
- de Galan BE, Perkovic V, Ninomiya T, et al.: Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883–892. CrossRef
- The GISEN Group: Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857–1863. CrossRef
- Esnault VLM, Brown EA, Apetrei E, et al.; Amlodipine Versus Enalapril in Renal Failure (AVER) Study Group: The effects of enalapril and amlodipine on renal function in adults with hypertension and non-diabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebocontrolled study. Clin Ther 2008, 30:482–498. CrossRef
- Richard S: Vascular effects of calcium-channel antagonists: new evidence. Drugs 2005, 65(Suppl 2):1–10.
- Martinez-Martin FJ, Saiz-Satjes M: Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther 2008, 6:1347–1355. CrossRef
- Fogari R, Corradi L, Zoppi A, et al.: Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens 2007, 20:1092–1096. CrossRef
- Bolignano D, Lacquaniti A, Coppolino G, et al.: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:337–344. CrossRef
- Bolignano D, Lacquaniti A, Coppolino G, et al.: Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009, 32:91–98. CrossRef
- Fliser D, Ritz E: Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001, 37:79–83.
- Shilpak MG, Sarnak MJ, Katz R, et al.: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352:2049–2060. CrossRef
- Peralta CA, Whooley MA, Ix JH, Shilpak MG: Kidney function and systolic blood pressure: new insights from cystatin C: data from the Heart and Soul Study. Am J Hypertens 2006, 19:939–946. CrossRef
- Effect of blood pressure lowering on markers of kidney disease progression
Current Hypertension Reports
Volume 11, Issue 5 , pp 368-374
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors